InvestorsHub Logo
Followers 0
Posts 13
Boards Moderated 0
Alias Born 10/26/2014

Re: None

Tuesday, 02/24/2015 4:42:21 PM

Tuesday, February 24, 2015 4:42:21 PM

Post# of 27557
From BARDA today - http://www.phe.gov/ASPRBlog/pages/BlogArticlePage.aspx?PostID=121

The Biomedical Advanced Research and Development Authority (BARDA) today took an exciting next step in implementing a three-prong strategy to develop, manufacture, test, and make available Ebola monoclonal antibody therapeutic candidates as part of the U.S. Ebola response. BARDA now is partnering with Medicago and Fraunhofer to produce Ebola monoclonal antibodies similar to ZMapp from Mapp BioPharmaceuticals to study efficacy in nonhuman primates and then potentially for clinical studies in humans.

Fraunhofer is working with Ibio and their platforms. They too are supported by Gates. So, this means that IBIO must be part of this too!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IBIO News